Published in J Caffeine Res on June 01, 2013
Caffeine's Attenuation of Cocaine-Induced Dopamine Release by Inhibition of Adenosine. J Caffeine Res (2014) 0.79
Caffeine and Substance Use Disorders. J Caffeine Res (2013) 0.75
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem (1962) 12.79
Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem (1958) 4.17
Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci (1995) 3.65
Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 3.52
Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci (1999) 3.43
Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol (2010) 3.38
Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science (1999) 3.23
Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci (2008) 3.08
Adenosine receptors and behavioral actions of methylxanthines. Proc Natl Acad Sci U S A (1981) 2.66
The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci (1990) 2.54
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide (2009) 2.00
Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev (2011) 1.93
An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem (2007) 1.87
Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci (1994) 1.85
Exchange of substrate and inhibitor specificities between adenylyl and guanylyl cyclases. J Biol Chem (1998) 1.66
Dependence of GABAergic synaptic areas on the interneuron type and target size. J Neurosci (2000) 1.60
Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci (2007) 1.48
Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology (2008) 1.45
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology (2003) 1.41
Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci (2001) 1.40
Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem (2004) 1.27
Regulation of striatal dopamine neurotransmission by nitric oxide: effector pathways and signaling mechanisms. Synapse (2002) 1.27
Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci (2002) 1.20
Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One (2011) 1.20
mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol (2003) 1.17
Soluble guanylyl cyclase: the nitric oxide receptor. Methods Enzymol (2005) 1.17
Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal (2009) 1.16
Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem (2004) 1.15
Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. Brain Res Rev (2007) 1.14
Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry (2000) 1.14
Synaptic connections between spiny neurons of the direct and indirect pathways in the neostriatum of the rat: evidence from dopamine receptor and neuropeptide immunostaining. Eur J Neurosci (1996) 1.10
Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol (2005) 1.10
Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis (2010) 1.07
Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology (2008) 1.06
Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology (Berl) (2002) 1.05
Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem (2007) 1.05
Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl) (2005) 1.03
Nitric oxide neurons and neurotransmission. Prog Neurobiol (2009) 1.02
Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther (1995) 0.99
Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine. J Pharmacol Exp Ther (1989) 0.97
Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica (1992) 0.95
A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl) (2005) 0.93
Pharmacokinetics and metabolism of natural methylxanthines in animal and man. Handb Exp Pharmacol (2011) 0.92
Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther (1990) 0.92
Cyclic GMP metabolism and its role in brain physiology. J Physiol Pharmacol (2005) 0.92
Effects of paraxanthine and caffeine on sleep, locomotor activity, and body temperature in orexin/ataxin-3 transgenic narcoleptic mice. Sleep (2010) 0.89
Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol (1991) 0.87
Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology (2012) 0.84
Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines. Food Chem Toxicol (1988) 0.84
Interstrain variation in acute toxic response to caffeine among inbred mice. Pharmacol Biochem Behav (1984) 0.81
Enhancement of caffeine-induced locomotor hyperactivity produced by the combination with L-arginine or taurine in mice: Possible involvement of nitric oxide. Methods Find Exp Clin Pharmacol (2009) 0.80
Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes. Eur J Pharmacol (1990) 0.78
Sensitivity of inbred mice to methylxanthines is not determined by plasma xanthine concentration. Neurosci Lett (1985) 0.78
Evidence for the role of nitric oxide in caffeine-induced locomotor activity in mice. Psychopharmacology (Berl) (2003) 0.77